Helen E Heslop

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/980912/publications.pdf

Version: 2024-02-01

394 papers	29,937 citations	5574 82 h-index	5255 165 g-index
400 all docs	400 docs citations	400 times ranked	18208 citing authors

#	Article	IF	Citations
1	Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. Journal of Allergy and Clinical Immunology, 2022, 149, 758-766.	2.9	6
2	High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Advances, 2022, 6, 452-459.	5.2	11
3	Beyond CD19 CAR-T cells in lymphoma. Current Opinion in Immunology, 2022, 74, 46-52.	5.5	3
4	Randomized Phase III BMT CTN Trial of Calcineurin Inhibitorâ€“Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. Journal of Clinical Oncology, 2022, 40, 356-368.	1.6	79
5	Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplantation, 2022, , .	2.4	2
6	Donor-derived multiple leukemia antigenâ€“specific T-cell therapy to prevent relapse after transplantÂin patients with ALL. Blood, 2022, 139, 2706-2711.	1.4	13
7	Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood, 2022, 140, 16-24.	1.4	14
8	Long Term Follow up for the Development of Subsequent Malignancies in Patients Treated with Genetically Modified Immune Effectors. Transplantation and Cellular Therapy, 2022, 28, S200-S201.	1.2	0
9	Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211071.	3.2	6
10	Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nature Biotechnology, 2021, 39, 56-63.	17.5	71
11	Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood, 2021, 137, 2585-2597.	1.4	38
12	Adoptive T-Cell Therapy for Epstein-Barr Virusâ€“Related Lymphomas. Journal of Clinical Oncology, 2021, 39, 514-524.	1.6	18
13	Taking T-Cell Oncotherapy Off-the-Shelf. Trends in Immunology, 2021, 42, 261-272.	6.8	14
14	T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. Journal of Clinical Oncology, 2021, 39, 1415-1425.	1.6	30
15	Stereotactic body radiation therapy and in situ oncolytic virus therapy followed by immunotherapy in metastatic non-small cell lung cancer.. Journal of Clinical Oncology, 2021, 39, 9115-9115.	1.6	4
16	Matched related hematopoietic cell transplant for sickle cell disease with alemtuzumab: the Texas Childrenâ€™s Hospital experience. Bone Marrow Transplantation, 2021, 56, 2797-2803.	2.4	6
17	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Annals of Hematology, 2021, 100, 2529-2539.	1.8	12
18	Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. Leukemia and Lymphoma, 2021, 62, 3256-3263.	1.3	11

#	Article	IF	Citations
19	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. Transplantation and Cellular Therapy, 2021, 27, 885-907.	1.2	12
20	Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies. Blood Advances, 2021, 5, 4630-4633.	5.2	4
21	Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy. Blood Cancer Discovery, 2021, 2, 408-422.	5.0	84
22	Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products. Transplantation and Cellular Therapy, 2021, 27, 785.e1-785.e6.	1.2	2
23	Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL. Blood, 2021, 138, 471-471.	1.4	0
24	Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial). Blood, 2021, 138, 3847-3847.	1.4	7
25	Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma. Blood, 2021, 138, 1763-1763.	1.4	6
26	Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma. Blood, 2021, 138, 654-654.	1.4	9
27	Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nature Communications, 2020, 11, 3549.	12.8	103
28	Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. Journal of Clinical Oncology, 2020, 38, 3794-3804.	1.6	235
29	The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Science Translational Medicine, 2020, 12, .	12.4	25
30	Modulating TNFÎ± activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. , 2020, 8, e001229.		29
31	Virus-Specific T Cells for the Treatment of Malignanciesâ€"Then, Now, and the Future. Current Stem Cell Reports, 2020, 6, 17-29.	1.6	4
32	CRISPR-Edited Immune Effectors: The End of the Beginning. Molecular Therapy, 2020, 28, 995-996.	8.2	3
33	CD5 CAR T-Cells for Treatment of Patients with Relapsed/Refractory CD5 Expressing T-Cell Lymphoma Demonstrates Safety and Anti-Tumor Activity. Biology of Blood and Marrow Transplantation, 2020, 26, S237.	2.0	12
34	Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. Biology of Blood and Marrow Transplantation, 2020, 26, e94-e100.	2.0	3
35	Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH. British Journal of Haematology, 2020, 188, e84-e87.	2.5	18
36	Outcomes of myeloablative, T cell deplete unrelated donor hematopoietic stem cell transplantation at a single center.. Journal of Clinical Oncology, 2020, 38, e19525-e19525.	1.6	0

#	Article	IF	Citations
37	Sensitizing Burkitt lymphoma to EBV-CTLs. Blood, 2020, 135, 1822-1823.	1.4	7
38	A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multiantigen specific T cells in the first-line setting (TACTOPS).. Journal of Clinical Oncology, 2020, 38, 4622-4622.	1.6	9
39	Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies.. Journal of Clinical Oncology, 2020, 38, 158-158.	1.6	0
40	A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma. Blood, 2020, 136, 16-16.	1.4	6
41	Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19. Blood, 2020, 136, 5-5.	1.4	2
42	Treatment of Severe, Drug-Refractory Viral Infections with Allogeneic, Off-the-Shelf Multi-Virus Specific T Cells in Patients Following HSCT: Results from a Phase 2 Study. Blood, 2020, 136, 2-3.	1.4	1
43	Survival outcomes of allogeneic hematopoietic cell transplants with EBVâ€positive or EBVâ€negative postâ€transplant lymphoproliferative disorder, A CIBMTR study. Transplant Infectious Disease, 2019, 21, e13145.	1.7	22
44	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2305-2321.	2.0	132
45	T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptorâ€“Expressing T Cells. Clinical Cancer Research, 2019, 25, 7340-7350.	7.0	32
46	Tâ€cell receptor sequencing demonstrates persistence of virusâ€specific T cells after antiviral immunotherapy. British Journal of Haematology, 2019, 187, 206-218.	2.5	29
47	The Impact of Donor Baseline Characteristics on Total Nucleated Cell Count in Marrow Products of Healthy Bone Marrow Donors. Biology of Blood and Marrow Transplantation, 2019, 25, S201.	2.0	0
48	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)â€“an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 2019, 54, 1868-1880.	2.4	86
49	Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells. Molecular Therapy, 2019, 27, 900-901.	8.2	3
50	Administering Leukemia-Directed Donor Lymphocytes to Patients with AML or MDS to Prevent or Treat Post-Allogeneic HSCT Relapse. Biology of Blood and Marrow Transplantation, 2019, 25, S10-S11.	2.0	6
51	CARâ€T cell therapy for nonâ€Hodgkin lymphomas: A new treatment paradigm. Advances in Cell and Gene Therapy, 2019, 2, e54.	0.9	8
52	Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR. Cancer Immunology Research, 2019, 7, 528-533.	3.4	23
53	Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2019, 25, S411-S412.	2.0	0
54	CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL). Biology of Blood and Marrow Transplantation, 2019, 25, S63.	2.0	14

#	Article	IF	Citations
55	Excellent Outcomes for Pediatric Non-Malignant Diseases Using Umbilical Cord Blood Transplantation (UCBT) Conditioned without Serotherapy in the Absence of a Matched Related Donor. Biology of Blood and Marrow Transplantation, 2019, 25, S13.	2.0	3
56	Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Advances, 2019, 3, 2689-2695.	5.2	9
57	â€œMiniâ€•bank of only 8 donors supplies CMV-directed T cells to diverse recipients. Blood Advances, 2019, 3, 2571-2580.	5.2	44
58	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e76-e85.	2.0	85
59	Harmonizing Immune Effector Toxicity Reporting. Biology of Blood and Marrow Transplantation, 2019, 25, e121-e122.	2.0	4
60	Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies. Blood, 2019, 134, 199-199.	1.4	53
61	Incorporation of Thiotepa in a Reduced Intensity Conditioning Regimen Leads to Improved Engraftment after Stem Cell Transplant for Patients with Hemophagocytic Lymphohistiocytosis. Blood, 2019, 134, 3273-3273.	1.4	0
62	High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 1643-1650.	2.0	24
63	Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood, 2018, 132, 89-100.	1.4	139
64	Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Molecular Therapy, 2018, 26, 1-2.	8.2	5
65	Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectivesâ€”A Single-Center Experience, 2008 to 2016. Biology of Blood and Marrow Transplantation, 2018, 24, 1424-1431.	2.0	15
66	Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biology of Blood and Marrow Transplantation, 2018, 24, 537-541.	2.0	21
67	Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. Journal of Clinical Oncology, 2018, 36, 1128-1139.	1.6	137
68	EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood, 2018, 132, 2351-2361.	1.4	49
69	InÂVivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkinâ€™s Lymphomas. Molecular Therapy, 2018, 26, 2727-2737.	8.2	180
70	A backpack revs up T-cell activity. Nature Biotechnology, 2018, 36, 702-703.	17.5	6
71	Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium. Cytotherapy, 2018, 20, 1182-1190.	0.7	6
72	CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL). Blood, 2018, 132, 680-680.	1.4	20

#	Article	IF	Citations
73	Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma. Blood, 2018, 132, 1014-1014.	1.4	2
74	Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor Associated Antigens. Blood, 2018, 132, 2693-2693.	1.4	0
75	Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells. Blood, 2018, 132, 1685-1685.	1.4	1
76	The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clinical Advances in Hematology and Oncology, 2018, 16, 375-386.	0.3	15
77	Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Molecular Therapy, 2017, 25, 249-258.	8.2	217
78	Fall of the mutants: T cells targeting BCR-ABL. Blood, 2017, 129, 539-540.	1.4	4
79	Exhausting alloreactivity of donor-derived CAR T cells. Nature Medicine, 2017, 23, 147-148.	30.7	4
80	HER2-Specific Chimeric Antigen Receptorâ€"Modified Virus-Specific T Cells for Progressive Glioblastoma. JAMA Oncology, 2017, 3, 1094.	7.1	608
81	Recent advances in Tâ€cell immunotherapy for haematological malignancies. British Journal of Haematology, 2017, 176, 688-704.	2.5	20
82	CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Molecular Therapy, 2017, 25, 2214-2224.	8.2	378
83	Adoptive Transfer of Multi-Tumor Antigen Specific T Cells as Treatment for Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, S50.	2.0	1
84	The Use of Donor Lymphocyte Infusions As Prophylaxis and Treatment for Relapse in Children Post Hematopoietic Cell Transplant for Malignant Disease: A Single Institution Experience. Biology of Blood and Marrow Transplantation, 2017, 23, S372-S373.	2.0	0
85	Administration of Banked, 3rd Party Multivirus-Specific T Cells to Treat Drug-Refractory EBV, CMV, AdV, HHV6, and BKV Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2017, 23, S58-S59.	2.0	0
86	Equal opportunity CAR T cells. Blood, 2017, 129, 3275-3277.	1.4	3
87	Clinical and immunological responses after CD30-specific chimeric antigen receptorâ€"redirected lymphocytes. Journal of Clinical Investigation, 2017, 127, 3462-3471.	8.2	301
88	Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2017, 35, 3547-3557.	1.6	367
89	Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma.. Journal of Clinical Oncology, 2017, 35, 10508-10508.	1.6	32
90	Checkpoint inhibition and cellular immunotherapy in lymphoma. Hematology American Society of Hematology Education Program, 2016, 2016, 390-396.	2.5	8

#	Article	IF	Citations
91	451. Robust Manufacture of CAR-T Cells. Molecular Therapy, 2016, 24, S179.	8.2	0
92	Outcomes after Matched Unrelated Donor Stem Cell Transplantation in Chronic Granulomatous Disease â€“ an Update. Biology of Blood and Marrow Transplantation, 2016, 22, S378.	2.0	0
93	Immunotherapy for Lymphoma Using T Cells Targeting Multiple Tumor-Associated Antigens. Biology of Blood and Marrow Transplantation, 2016, 22, S44-S45.	2.0	3
94	Go-Rex: A Novel in Vitro System for the Assessment of CAR T Cell Function. Biology of Blood and Marrow Transplantation, 2016, 22, S425.	2.0	0
95	A PHASE 1 Perspective: Multivirus-Specific T CELLS from BOTH Cord Blood and BONE Marrow Transplant Donors. Biology of Blood and Marrow Transplantation, 2016, 22, S140-S141.	2.0	0
96	IVIG Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant: A Retrospective Analysis of Monthly Intravenous Immunoglobulin Infusion vs. IgG Level Based Dosing. Biology of Blood and Marrow Transplantation, 2016, 22, S244.	2.0	0
97	An Optimized Process of Generating CAR-T Cells for Clinical Applications. Biology of Blood and Marrow Transplantation, 2016, 22, S386.	2.0	0
98	New ISSCR guidelines: clinical translation of stem cell research. Lancet, The, 2016, 387, 1979-1981.	13.7	42
99	Setting Global Standards for Stem Cell Research and Clinical Translation: TheÂ2016 ISSCR Guidelines. Stem Cell Reports, 2016, 6, 787-797.	4.8	172
100	T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood, 2016, 127, 3331-3340.	1.4	177
101	Fine-tuning the CAR spacer improves T-cell potency. OncoImmunology, 2016, 5, e1253656.	4.6	137
102	Forecasting Cytokine Storms with New Predictive Biomarkers. Cancer Discovery, 2016, 6, 579-580.	9.4	10
103	Respiratory Viral Infections after Hematopoietic Stem Cell Transplants : The Texas Children's Hospital Experience. Biology of Blood and Marrow Transplantation, 2016, 22, S256-S257.	2.0	1
104	Matched Unrelated Allogeneic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia: Texas Children's Hospital Experience. Biology of Blood and Marrow Transplantation, 2016, 22, S237.	2.0	1
105	Chimeric T-Cells for Therapy of CD30+ Hodgkin and Non-Hodgkin Lymphomas (HL & NHL). Biology of Blood and Marrow Transplantation, 2016, 22, S145-S146.	2.0	1
106	Intravesicular Cidofovir for BK Hemorrhagic Cystitis in Pediatric Patients after Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2016, 22, S163-S164.	2.0	3
107	Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. Molecular Therapy, 2016, 24, 736-745.	8.2	11
108	Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. Journal of Allergy and Clinical Immunology, 2016, 137, 1498-1505.e1.	2.9	117

#	Article	IF	Citations
109	Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Molecular Therapy, 2016, 24, 823-831.	8.2	30
110	CAR-T Cell Therapy for Lymphoma. Annual Review of Medicine, 2016, 67, 165-183.	12.2	123
111	Policy: Global standards for stem-cell research. Nature, 2016, 533, 311-313.	27.8	41
112	Clinical responses with T lymphocytes targeting malignancy-associated Îº light chains. Journal of Clinical Investigation, 2016, 126, 2588-2596.	8.2	241
113	Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling. Blood, 2016, 128, 1851-1851.	1.4	22
114	Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2016, 128, 501-501.	1.4	2
115	Rapidly-Generated EBV-Specific T Cells (EBVST-cells) to Treat Type 2 Latency Lymphoma. Blood, 2016, 128, 2990-2990.	1.4	0
116	Umbilical Cord Blood Transplantation Conditioned without Serotherapy Is an Excellent Curative Alternative for Pediatric Non-Malignant Diseases. Biology of Blood and Marrow Transplantation, 2015, 21, S103-S104.	2.0	0
117	Outcomes after Allogeneic Stem Cell Transplantation for Patients with Non-Hodgkin Lymphoma: Texas Children's Hospital Experience 1999-2013. Biology of Blood and Marrow Transplantation, 2015, 21, S211-S212.	2.0	0
118	Administration of LMP-Specific Cytotoxic T-Lymphocytes to Patients with Relapsed EBV-Positive Lymphoma Post Allogeneic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2015, 21, S148.	2.0	1
119	Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood, 2015, 125, 3905-3916.	1.4	260
120	518. Artificial Mouse Model: An Animal-Free System for Assessment of CAR-T Cell Function. Molecular Therapy, 2015, 23, S207-S208.	8.2	0
121	722. Overcoming EBV Tumor Specific T-Cell Anergy in Rapidly-Generated EBVST-Cells for Adoptive Transfer Therapy. Molecular Therapy, 2015, 23, S288.	8.2	0
122	Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2015, 21, 1266-1272.	2.0	24
123	Optimized manufacturing process for the generation of clinical grade CAR T cells. Cytotherapy, 2015, 17, S82.	0.7	0
124	Antigen-specific T cell therapies for cancer: Figure 1.. Human Molecular Genetics, 2015, 24, R67-R73.	2.9	32
125	CMV-specific T cells generated from naÃ¯ve T cells recognize atypical epitopes and may be protective in vivo. Science Translational Medicine, 2015, 7, 285ra63.	12.4	93
126	Safety of multiple doses of car T cells. Cytotherapy, 2015, 17, S12-S13.	0.7	0

#	Article	IF	Citations
127	Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood, 2015, 125, 4103-4113.	1.4	188
128	Human Epidermal Growth Factor Receptor 2 (HER2) â€“Specific Chimeric Antigen Receptorâ€“Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. Journal of Clinical Oncology, 2015, 33, 1688-1696.	1.6	778
129	Late-Onset Severe Chronic Active EBV in a Patient for FiveÂYears with Mutations in STXBP2 (MUNC18-2) and PRF1 (Perforin 1). Journal of Clinical Immunology, 2015, 35, 445-448.	3.8	27
130	Adoptive T-Cell Therapy to Prevent and Treat Human Metapneumovirus (hMPV) Infections Post Hematopoietic Stem Cell Transplant (HSCT). Biology of Blood and Marrow Transplantation, 2015, 21, S170.	2.0	3
131	Graft Versus Leukemia Response Without Graft-versus-host Disease Elicited By Adoptively Transferred Multivirus-specific T-cells. Molecular Therapy, 2015, 23, 179-183.	8.2	28
132	Survivin-specific T cell receptor targets tumor but not T cells. Journal of Clinical Investigation, 2015, 125, 157-168.	8.2	56
133	Chimeric T Cells for Therapy of CD30+ Hodgkin and Non-Hodgkin Lymphomas. Blood, 2015, 126, 185-185.	1.4	18
134	Immunotherapy for Lymphoma Using T Cells Targeting Multiple Tumor Associated Antigens. Blood, 2015, 126, 186-186.	1.4	13
135	Safety of Multiple Doses of CAR T Cells. Blood, 2015, 126, 4425-4425.	1.4	5
136	Allogeneic Stem Cell Transplantation in a Pediatric Patient with Whim Syndrome. Blood, 2015, 126, 5528-5528.	1.4	4
137	Autologous HER2 CMV bispecific CAR T cells for progressive glioblastoma: Results from a phase I clinical trial.. Journal of Clinical Oncology, 2015, 33, 3008-3008.	1.6	44
138	Matched Unrelated Allogeneic Stem Cell Transplantation for Patients with Congenital Amegakaryocytic Thrombocytopenia: Texas Children`s Hospital Experience. Blood, 2015, 126, 5529-5529.	1.4	0
139	Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2015, 126, 622-622.	1.4	0
140	Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years. Blood, 2015, 126, 1926-1926.	1.4	0
141	Optimizing the production of suspension cells using the G-Rex â€œMâ€•series. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14015.	4.1	71
142	Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor. Molecular Therapy, 2014, 22, 1211-1220.	8.2	145
143	Systemic Inflammatory Response Syndrome After Administration of Unmodified T Lymphocytes. Molecular Therapy, 2014, 22, 1134-1138.	8.2	28
144	Antiviral Tâ€cell therapy. Immunological Reviews, 2014, 258, 12-29.	6.0	58

#	Article	IF	Citations
145	T lymphocytes targeting native receptors. Immunological Reviews, 2014, 257, 39-55.	6.0	34
146	Reply to S. Yuan et al. Journal of Clinical Oncology, 2014, 32, 2820-2821.	1.6	0
147	Epsteinâ€“Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Current Opinion in Hematology, 2014, 21, 476-481.	2.5	51
148	Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCT. Science Translational Medicine, 2014, 6, 242ra83.	12.4	357
149	Immunotherapy: opportunities, risks and future perspectives. Cytotherapy, 2014, 16, S120-S129.	0.7	8
150	Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins. Journal of Clinical Oncology, 2014, 32, 798-808.	1.6	433
151	Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity. Clinical Cancer Research, 2014, 20, 2215-2225.	7.0	176
152	Combining Drugs and Biologics to Treat Nasopharyngeal Cancer. Molecular Therapy, 2014, 22, 8-9.	8.2	5
153	Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells. Molecular Therapy, 2014, 22, 623-633.	8.2	113
154	Outcome after Stem Cell Transplant in Patients with Dyskeratosis Congenita. Biology of Blood and Marrow Transplantation, 2014, 20, S178-S179.	2.0	0
155	Refined/Accelerated T Cell Therapies for the Treatment of EBV+ Lymphomas. Biology of Blood and Marrow Transplantation, 2014, 20, S134.	2.0	0
156	Extending the Option of CMV-Specific T Cells from the CMV-Seronegative Donor. Biology of Blood and Marrow Transplantation, 2014, 20, S131.	2.0	0
157	Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood, 2014, 123, 3750-3759.	1.4	534
158	Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood, 2014, 123, 3895-3905.	1.4	161
159	Genetic modification of T cells with a novel bispecific chimeric antigen receptor to enhance the control of high-grade glioma (HGG).. Journal of Clinical Oncology, 2014, 32, 10027-10027.	1.6	7
160	Graft Versus Leukemia Response without Graft Versus Host Disease Elicited By Adoptively Transferred Multivirus-Specific T-Cells. Blood, 2014, 124, 2439-2439.	1.4	0
161	T Cells Expressing CD19-Specific Chimeric Antigen Receptors Are Inhibited By Indoleamine 2,3-Dioxygenase in Tumors. Blood, 2014, 124, 2434-2434.	1.4	0
162	Bi-Specific T Cell Therapy for Pancreatic Cancer. Biology of Blood and Marrow Transplantation, 2013, 19, S347-S348.	2.0	0

#	Article	IF	Citations
163	Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood, 2013, 121, 207-218.	1.4	76
164	Genetic engineering of T-cell receptors: TCR takes to titin. Blood, 2013, 122, 853-854.	1.4	4
165	Interleukin 15 Provides Relief to CTLs from Regulatory T Cellâ€“Mediated Inhibition: Implications for Adoptive T Cellâ€“Based Therapies for Lymphoma. Clinical Cancer Research, 2013, 19, 106-117.	7.0	68
166	Outcomes After Second Allogeneic Transplants in Pediatric Patients With Relapsed Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2013, 19, S253.	2.0	0
167	New Approaches in Alternative Donor Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, S91-S96.	2.0	4
168	Safety and Clinical Efficacy of Rapidly-Generated Trivirus-Directed T Cells After Allogeneic Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2013, 19, S111.	2.0	3
169	Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Molecular Therapy, 2013, 21, 2113-2121.	8.2	200
170	T-cell therapy for viral infections. Hematology American Society of Hematology Education Program, 2013, 2013, 342-347.	2.5	30
171	Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma. Molecular Therapy, 2013, 21, 2087-2101.	8.2	300
172	Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood, 2013, 121, 5113-5123.	1.4	507
173	Pharmacotherapy versus T lymphocytes for CMV. Blood, 2013, 121, 3544-3545.	1.4	2
174	Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood, 2013, 122, 2965-2973.	1.4	470
175	Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica, 2013, 98, 533-537.	3.5	30
176	Plasma Markers of B-Cell Activation and Clonality in Pediatric Liver and Hematopoietic Stem Cell Transplant Recipients. Transplantation, 2013, 95, 519-526.	1.0	15
177	Multi-Virus-Specific T-Cell Therapy For Patients After Hematopoietic Stem Cell and Cord Blood Transplantation. Blood, 2013, 122, 140-140.	1.4	16
178	Safety and Clinical Efficacy Of Rapidly-Generated Virus-Specific T Cells With Activity Against Adv, EBV, CMV, HHV6 and BK Virus Administered After Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2013, 122, 148-148.	1.4	2
179	Clinical Responses In Patients Infused With T Lymphocytes Redirected To Target Îº-Light Immunoglobulin Chain. Blood, 2013, 122, 506-506.	1.4	6
180	Whole genome sequencing of sporadic Burkitt lymphoma in HIV-infected and uninfected patients.. Journal of Clinical Oncology, 2013, 31, 8577-8577.	1.6	0

#	Article	IF	Citations
181	A â€œnon-fratricidalâ€•Î±Î²- T Cell Receptor That Targets Survivin Expressed By Hematological Malignancies. Blood, 2013, 122, 141-141.	1.4	0
182	Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections. Molecular Therapy, 2012, 20, 1622-1632.	8.2	238
183	T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nature Reviews Clinical Oncology, 2012, 9, 510-519.	27.6	230
184	Replication-Competent Retroviruses in Gene-Modified T Cells Used in Clinical Trials: Is It Time to Revise the Testing Requirements?. Molecular Therapy, 2012, 20, 246-249.	8.2	54
185	Equal-opportunity treatment of EBV-PTLD. Blood, 2012, 119, 2436-2438.	1.4	7
186	Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epsteinâ€“Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy, 2012, 14, 7-11.	0.7	39
187	Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. Journal of Allergy and Clinical Immunology, 2012, 129, 176-183.	2.9	67
188	Aggressive peripheral CD70â€positive tâ€cell lymphoma associated with severe chronic active EBV infection. Pediatric Blood and Cancer, 2012, 59, 758-761.	1.5	5
189	Improving Immune Reconstitution After Cord Blood Transplantation Using Ex Vivo Expanded Virus-Specific T Cells: A Phase I Clinical Study. Blood, 2012, 120, 224-224.	1.4	2
190	Optimizing the Manufacture of CAR-T Cells for Clinical Applications. Blood, 2012, 120, 348-348.	1.4	1
191	Multicenter Study of â€œoff-the-Shelfâ€•Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT). Blood, 2012, 120, 457-457.	1.4	2
192	Human papillomavirus type 16 (HPV16) E6/E7-specific cytotoxicÂT lymphocytes (CTL) for immunotherapy of HPV-associated cancer (Ca).. Journal of Clinical Oncology, 2012, 30, 2558-2558.	1.6	0
193	Safety and Clinical Efficacy of Rapidly-Generated Trivirus-Directed T Cells After Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2012, 120, 223-223.	1.4	25
194	Expansion of T cells targeting multiple antigens of cytomegalovirus, Epsteinâ€“Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy, 2011, 13, 976-986.	0.7	50
195	Guidance for Developing Phase II Cell Therapy Trial Proposals for Consideration by the Blood and Marrow Transplant Clinical Trials Network. Biology of Blood and Marrow Transplantation, 2011, 17, 192-196.	2.0	1
196	Genetic Modification of T Cells. Biology of Blood and Marrow Transplantation, 2011, 17, S15-S20.	2.0	30
197	Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia. Cytotherapy, 2011, 13, 1128-1139.	0.7	15
198	Definitions of histocompatibility typing terms: Harmonization of Histocompatibility Typing Terms Working Group. Human Immunology, 2011, 72, 1214-1216.	2.4	30

#	Article	IF	Citations
199	Definitions of histocompatibility typing terms. Blood, 2011, 118, e180-e183.	1.4	79
200	Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4. Clinical Cancer Research, 2011, 17, 7058-7066.	7.0	72
201	Posttransplant lymphoproliferative disease following liver transplantation. Current Opinion in Organ Transplantation, 2011, 16, 274-280.	1.6	80
202	Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood, 2011, 117, 5835-5849.	1.4	241
203	A less sour sweet; blocking galectin. Blood, 2011, 117, 4165-4166.	1.4	2
204	Antitumor activity and long-term fate of chimeric antigen receptorâ€“positive T cells in patients with neuroblastoma. Blood, 2011, 118, 6050-6056.	1.4	984
205	TCR expression; quantitative easing by CD3. Blood, 2011, 118, 3452-3453.	1.4	0
206	Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60â€“78â€ƒyears of age. British Journal of Haematology, 2011, 153, 76-82.	2.5	51
207	High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood, 2011, 117, 3353-3362.	1.4	100
208	Children with acute leukemia: A comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation. Pediatric Blood and Cancer, 2011, 56, 143-151.	1.5	9
209	Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma. Molecular Therapy, 2011, 19, 2258-2268.	8.2	80
210	Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy. New England Journal of Medicine, 2011, 365, 1673-1683.	27.0	1,264
211	Getting Personal with Melanoma. Clinical Cancer Research, 2011, 17, 4189-4191.	7.0	2
212	Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Human Molecular Genetics, 2011, 20, R93-R99.	2.9	29
213	CD28 costimulation improves expansion and persistence of chimeric antigen receptorâ€“modified T cells in lymphoma patients. Journal of Clinical Investigation, 2011, 121, 1822-1826.	8.2	876
214	Phase I Study to Improve Virus-Specific Immune Reconstitution After Cord Blood Transplantation Using Cord Blood-Derived Virus-Specific Cytotoxic T Lymphocytes. Blood, 2011, 118, 155-155.	1.4	4
215	Infusion of CD19-Directed and Multivirus Specific Cytotoxic T Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation for B Cell Malignancies,. Blood, 2011, 118, 4083-4083.	1.4	1
216	Crosstalk between Medulloblastoma Cells and Endothelium Triggers a Strong Chemotactic Signal Recruiting T Lymphocytes to the Tumor Microenvironment. PLoS ONE, 2011, 6, e20267.	2.5	26

#	Article	IF	Citations
217	Complete Tumor Responses in Lymphoma Patients Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein Barr Virus (EBV) - Latent Membrane Proteins. Blood, 2011, 118, 956-956.	1.4	1
218	Towards Phase 2/3 Trials for Epstein - Barr Virus (EBV)-Associated Malignancies,. Blood, 2011, 118, 4043-4043.	1.4	0
219	Human Papillomavirus Type 16 (HPV16) E6/E7-Specific Cytotoxic T Lymphocytes (CTLs) for Immunotherapy of HPV-Associated Malignancies. Blood, 2011, 118, 1913-1913.	1.4	0
220	Genetic Modification of Multi Leukemia Antigen-Specific Cytotoxic T Lymphocytes (CTL) to Enhance In Vivo Safety and Persistency. Blood, 2011, 118, 644-644.	1.4	0
221	Naiˆve T Cell-Derived CTL Recognize Atypical Epitopes of CMVpp65 with Higher Avidity Than CMV-Seropositive Donor-Derived CTL â€“ a Basis for Treatment of Post-Transplant Viral Infection by Adoptive Transfer of T Cells From Virus-naiˆve Donors. Blood, 2011, 118, 3002-3002.	1.4	0
222	Accelerated Production of Antigen-specific T Cells for Preclinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex). Journal of Immunotherapy, 2010, 33, 305-315.	2.4	144
223	Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood, 2010, 115, 925-935.	1.4	721
224	Adoptive T cell therapy of cancer. Current Opinion in Immunology, 2010, 22, 251-257.	5.5	111
225	An Inducible Caspase 9 Suicide Gene to Improve the Safety of Mesenchymal Stromal Cell Therapies. Stem Cells, 2010, 28, 1107-1115.	3.2	80
226	HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors. Clinical Cancer Research, 2010, 16, 474-485.	7.0	324
227	Safer CARS. Molecular Therapy, 2010, 18, 661-662.	8.2	71
228	Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leukemia and Lymphoma, 2010, 51, 870-880.	1.3	44
229	Preparing for Growth: Current Capacity and Challenges in Hematopoietic Stem Cell Transplantation Programs. Biology of Blood and Marrow Transplantation, 2010, 16, 595-597.	2.0	14
230	The Costs and Cost-Effectiveness of Allogeneic Peripheral Blood Stem Cell Transplantation versus Bone Marrow Transplantation in Pediatric Patients with Acute Leukemia. Biology of Blood and Marrow Transplantation, 2010, 16, 1272-1281.	2.0	39
231	Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy, 2010, 12, 743-749.	0.7	75
232	Computer-Assisted Quantitative Evaluation of Therapeutic Responses for Lymphoma Using Serial PET/CT Imaging. Academic Radiology, 2010, 17, 479-488.	2.5	12
233	Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood, 2010, 115, 2695-2703.	1.4	105
234	Allogeneic Virus-Specific T Cells with HLA Alloreactivity Do Not Produce Graft-Versus-Host Disease In Human Subjects. Blood, 2010, 116, 1252-1252.	1.4	1

#	Article	IF	Citations
235	Administration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-ÃŸ to Patients with EBV-Associated Lymphomas. Blood, 2010, 116, 560-560.	1.4	5
236	Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection with Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT). Blood, 2010, 116, 829-829.	1.4	98
237	Expansion of Lymphocytes for Cell-Based Therapeutics. Blood, 2010, 116, SCI-48-SCI-48.	1.4	0
238	The Effects of Co-Stimulatory Endodomains on the Fate of T Cells Expressing a Tumor Directed Chimeric Antigen Receptor (CAR) In Human Subjects with B Cell Malignancies. Blood, 2010, 116, 3949-3949.	1.4	0
239	CASPALLO: Phase I Clinical Trial of Allodepleted T Cells Transduced with Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation. Blood, 2010, 116, 559-559.	1.4	1
240	Genetic Manipulation of Tumor-specific Cytotoxic T Lymphocytes to Restore Responsiveness to IL-7. Molecular Therapy, 2009, 17, 880-888.	8.2	88
241	Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression. Molecular Therapy, 2009, 17, 1779-1787.	8.2	171
242	Nucleofection of DCs to Generate Multivirus-specific T Cells for Prevention or Treatment of Viral Infections in the Immunocompromised Host. Molecular Therapy, 2009, 17, 1616-1625.	8.2	68
243	How I treat EBV lymphoproliferation. Blood, 2009, 114, 4002-4008.	1.4	287
244	Impending Challenges in the Hematopoietic Stem Cell Transplantation Physician Workforce. Biology of Blood and Marrow Transplantation, 2009, 15, 1493-1501.	2.0	48
245	Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood, 2009, 113, 2442-2450.	1.4	107
246	T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood, 2009, 113, 6392-6402.	1.4	458
247	Generation of Epstein-Barr virusâ€“specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood, 2009, 114, 4784-4791.	1.4	86
248	Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood, 2009, 114, 4283-4292.	1.4	311
249	IL15 Enhances Proliferation and Effector Function of Antigen-Specific Cytotoxic T Lymphocytes (CTLs) and Mitigates the Suppressive Action of Regulatory T Cells (Tregs).. Blood, 2009, 114, 4088-4088.	1.4	1
250	Cytotoxic T Lymphocytes (CTL) Specific for CMV, Adenovirus, and EBV Can Be Generated From Naive T Cells for Adoptive Immunotherapy.. Blood, 2009, 114, 504-504.	1.4	0
251	An Inducible Caspase 9 Suicide Gene to Improve the Safety of Mesenchymal Stromal Cell Therapies.. Blood, 2009, 114, 1444-1444.	1.4	0
252	Adverse Events Following Infusion of T Cells for Adoptive Immunotherapy: A 10 Year Experience.. Blood, 2009, 114, 3212-3212.	1.4	0

#	Article	IF	Citations
253	Broad Spectrum Tumor Antigen-Specific Cytotoxic T Lymphocytes (CTL) for Therapy of Hematological Malignancy.. Blood, 2009, 114, 4083-4083.	1.4	1
254	Immune-Based Therapies Targeting Mage-A4 for Relapsed/Refractory Hodgkin's Lymphoma After Stem Cell Transplant.. Blood, 2009, 114, 4089-4089.	1.4	7
255	Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nature Medicine, 2008, 14, 1264-1270.	30.7	1,063
256	Cytotoxic T lymphocytes as immuneâ€therapy in haematological practice. British Journal of Haematology, 2008, 143, 169-179.	2.5	35
257	Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Practice and Research in Clinical Haematology, 2008, 21, 405-420.	1.7	24
258	Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens. Update on Cancer Therapeutics, 2008, 3, 33-41.	0.4	10
259	Comparable Outcome of Alternative Donor and Matched Sibling Donor Hematopoietic Stem Cell Transplant for Children with Acute Lymphoblastic Leukemia in First or Second Remission Using Alemtuzumab in a Myeloablative Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2008, 14, 1245-1252.	2.0	45
260	Successful Treatment of Stem Cell Graft Failure in Pediatric Patients Using a Submyeloablative Regimen of Campath-1H and Fludarabine. Biology of Blood and Marrow Transplantation, 2008, 14, 1298-1304.	2.0	21
261	Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy. Journal of Virology, 2008, 82, 546-554.	3.4	129
262	The Clone Ranger?. Molecular Therapy, 2008, 16, 1520-1521.	8.2	3
263	Allogeneic Hematopoietic Cell Transplants in Patients with Myelofibrosis Age 60 and Older. Blood, 2008, 112, 2798-2798.	1.4	1
264	Monoculture-Derived T Lymphocytes Providing Multiple Virus Specificity and Anti-Leukemia Activity for Recipients of Hematopietic Stem Cells or Umbilical Cord Blood Transplants. Blood, 2008, 112, 3909-3909.	1.4	1
265	Adoptive Immunotherapy with Memory T Cells.. Blood, 2008, 112, sci-25-sci-25.	1.4	1
266	Generation of Epstein Barr Virus Specific Cytotoxic T Lymphocytes (EBVCTLs) Resistant to the Immunosuppressive Drug Tacrolimus (FK506). Blood, 2008, 112, 3536-3536.	1.4	0
267	Complete Tumor Responses in Lymphoma Patients Who Receive Autologous Cytotoxic T Lymphocytes Targeting EBV Latent Membrane Proteins. Blood, 2008, 112, 230-230.	1.4	0
268	Multivirus-Specific T Cell Immunotherapy to Prevent or Treat Infections of Stem Cell Transplant Recipients.. Blood, 2008, 112, 2207-2207.	1.4	0
269	The â€œSide-Populationâ€•of Human Lymphoma Cells Have Increased Chemo-Resistance, Stem-Cell Like Properties and Are Potential Targets for Immunotherapy. Blood, 2008, 112, 2620-2620.	1.4	0
270	Rapid Generation of Antigen-Specific T Cells for Pre-Clinical and Clinical Applications Using a Novel Mini Cell Bioreactor. Blood, 2008, 112, 208-208.	1.4	0

#	Article	IF	Citations
271	Vaccination Strategies for Patients with B-CLL.. Blood, 2008, 112, 2106-2106.	1.4	0
272	Exploiting Cytokine Secretion to Rapidly Produce Multivirus-Specific T Cells for Adoptive Immunotherapy. Blood, 2008, 112, 4594-4594.	1.4	0
273	Cytotoxic T Lymphocytes (CTL) Specific for Adenovirus and CMV Can Be Generated from Umbilical Cord Blood for Adoptive Immunotherapy. Blood, 2008, 112, 3505-3505.	1.4	0
274	Safely Improving the in Vivo Survival of Tumor Specific Cytotoxic T Lymphocytes by Co-Transfer of IL7 Receptor Alpha Chain and icaspase9. Blood, 2008, 112, 3534-3534.	1.4	0
275	Polyclonal PRAME-Specific Cytotoxic T Lymphocytes Generated Using Protein-Spanning Pools of Overlapping Pentadecapeptides Target Chronic Myeloid Leukemia. Blood, 2008, 112, 3899-3899.	1.4	0
276	Engineering CD19-Redirected T Lymphocytes to Enhance Their Safety and Efficacy. Blood, 2008, 112, 824-824.	1.4	0
277	Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells. Cancer Research, 2007, 67, 5957-5964.	0.9	153
278	A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood, 2007, 109, 2657-2662.	1.4	83
279	Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood, 2007, 110, 2838-2845.	1.4	266
280	A Single Institution Experience With Pediatric Nasopharyngeal Carcinoma: High Incidence of Toxicity Associated With Platinum-based Chemotherapy Plus IMRT. Journal of Pediatric Hematology/Oncology, 2007, 29, 500-505.	0.6	23
281	Inducible Caspase 9 Suicide Gene to Improve the Safety of Allodepleted T Cells after Haploidentical Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 913-924.	2.0	181
282	Gene Transfer of IL-7R alpha (IL-7RÎ±) on Antigen-Specific Cytotoxic T Cells (CTLs) Restores Their Ability To Respond to IL-7 Cytokine.. Blood, 2007, 110, 2756-2756.	1.4	2
283	Preferentially Expressed Antigen of Melanoma (PRAME)-Specific Cytotoxic T-Lymphocytes (CTLs) and Transgenic T Cells To Target Chronic Myelogenous Leukemia (CML).. Blood, 2007, 110, 2761-2761.	1.4	10
284	In vivoexpansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leukemia and Lymphoma, 2006, 47, 837-842.	1.3	27
285	Administration of Latent Membrane Protein 2â€“Specific Cytotoxic T Lymphocytes to Patients with Relapsed Epstein-Barr Virusâ€“Positive Lymphoma. Clinical Lymphoma and Myeloma, 2006, 6, 342-347.	1.4	19
286	Comparable Outcomes of Matched-Related and Alternative Donor Stem Cell Transplantation for Pediatric Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2006, 12, 1277-1284.	2.0	96
287	Adoptive cellular immunotherapy. , 2006, , 648-660.		0
288	Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood, 2006, 107, 1332-1341.	1.4	71

#	Article	IF	Citations
289	Suicide is painless. Blood, 2006, 107, 2211-2212.	1.4	1
290	T lymphocytes redirected against the Îº light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood, 2006, 108, 3890-3897.	1.4	258
291	Treatment of solid organ transplant recipients with autologous Epstein Barr virusâ€“specific cytotoxic T lymphocytes (CTLs). Blood, 2006, 108, 2942-2949.	1.4	241
292	Viral lymphomagenesis. Current Opinion in Hematology, 2006, 13, 254-259.	2.5	10
293	Adoptive Tâ€cell transfer in cancer immunotherapy. Immunology and Cell Biology, 2006, 84, 281-289.	2.3	38
294	Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clinical Transplantation, 2006, 20, 389-393.	1.6	56
295	Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clinical Transplantation, 2006, 20, 689-694.	1.6	52
296	Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nature Medicine, 2006, 12, 1160-1166.	30.7	536
297	766. Immunotherapy for Her2-Positive Medulloblastoma: Regression of Experimental Tumors by Transfer of Her2-Redirected T Cells In Vivo. Molecular Therapy, 2006, 13, S296.	8.2	0
298	T Cell Immunotherapy for Adenoviral Infections of Stem Cell Transplant Recipients.. Blood, 2006, 108, 591-591.	1.4	3
299	Transgenic Expression of IL15 Selectively Expands Antigen Specific Cytotoxic T Cells (CTLs) Enhancing Their Anti-Tumor Effect In Vivo.. Blood, 2006, 108, 1721-1721.	1.4	0
300	Treatment of nasopharyngeal carcinoma with Epstein-Barr virusâ€“specific T lymphocytes. Blood, 2005, 105, 1898-1904.	1.4	344
301	An inducible caspase 9 safety switch for T-cell therapy. Blood, 2005, 105, 4247-4254.	1.4	607
302	To T-cell deplete or not. Blood, 2005, 106, 2932-2932.	1.4	0
303	Cellular Immunity to Epstein-Barr Virus in Liver Transplant Recipients Treated with Rituximab for Post-Transplant Lymphoproliferative Disease. American Journal of Transplantation, 2005, 5, 566-572.	4.7	75
304	Quantitative EBV Viral Loads and Immunosuppression Alterations can Decrease PTLD Incidence in Pediatric Liver Transplant Recipients. American Journal of Transplantation, 2005, 5, 2222-2228.	4.7	245
305	Biology and Treatment of Epstein-Barr Virusâ€“Associated Non-Hodgkin Lymphomas. Hematology American Society of Hematology Education Program, 2005, 2005, 260-266.	2.5	95
306	A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Molecular Therapy, 2005, 12, 933-941.	8.2	426

#	Article	IF	Citations
307	Characterization of Latent Membrane Protein 2 Specificity in CTL Lines from Patients with EBV-Positive Nasopharyngeal Carcinoma and Lymphoma. Journal of Immunology, 2005, 175, 4137-4147.	0.8	72
308	Adoptive Immunotherapy for EBV-associated Malignancies. Leukemia and Lymphoma, 2005, 46, 1-10.	1.3	104
309	Hemolytic Uremic Syndrome after Bone Marrow Transplantation: Clinical Characteristics and Outcome in Children. Biology of Blood and Marrow Transplantation, 2005, 11, 912-920.	2.0	51
310	Post-Transplant Lymphoproliferative Disorders. Annual Review of Medicine, 2005, 56, 29-44.	12.2	395
311	Outcome of Alternative Donor Transplantation for Severe Aplastic Anemia Can Be Comparable to Outcome with Matched Related Donors.. Blood, 2005, 106, 2052-2052.	1.4	0
312	Transplantation from Matched Unrelated Donors (MUD) for Thalassemia and Other Congenital Red Cell Disorders.. Blood, 2005, 106, 2746-2746.	1.4	0
313	Genetically Modified Her2-Specific T Cells Recognize Low and High Her2 Expressing Breast Cancer Cells.. Blood, 2005, 106, 5540-5540.	1.4	0
314	The Clinical Use of Donor-Derived Virus-Specific Cytotoxic T Lymphocytes Reactive Against Cytomegalovirus (CMV), Adenovirus and Epstein Barr Virus (EBV).. Blood, 2005, 106, 81-81.	1.4	0
315	The Use of Autologous LMP2-Specific Cytotoxic T Lymphocytes (CTL) for the Treatment of Relapsed EBV-Positive Hodgkin Disease and Non-Hodgkin Lymphoma.. Blood, 2005, 106, 773-773.	1.4	0
316	Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease. Journal of Experimental Medicine, 2004, 200, 1623-1633.	8.5	371
317	Evidence for the Presentation of Major Histocompatibility Complex Class Iâ€“restricted Epstein-Barr Virus Nuclear Antigen 1 Peptides to CD8+ T Lymphocytes. Journal of Experimental Medicine, 2004, 199, 459-470.	8.5	140
318	Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain, 2004, 127, 996-1008.	7.6	84
319	A strategy for treatment of Epsteinâ€“Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Therapy, 2004, 11, 81-91.	4.6	74
320	Transfusion-related acute lung injury (TRALI) following allogeneic stem cell transplant for acute myeloid leukemia. American Journal of Hematology, 2004, 75, 48-51.	4.1	29
321	Cellular therapy of Epsteinâ€“Barr-virus-associated post-transplant lymphoproliferative disease. Best Practice and Research in Clinical Haematology, 2004, 17, 401-413.	1.7	17
322	Adoptive immunotherapy for posttransplantation viral infections. Biology of Blood and Marrow Transplantation, 2004, 10, 143-155.	2.0	76
323	Treatment of Epstein-Barr Virus Lymphoproliferative Disease after Hematopoietic Stem-Cell Transplantation with Hydroxyurea and Cytotoxic T-Cell Lymphocytes. Transplantation, 2004, 78, 755-757.	1.0	38
324	Graft-versus-yogurt. Blood, 2004, 103, 4000-4001.	1.4	0

#	Article	IF	Citations
325	Dimerize and die. Blood, 2004, 103, 1177-1178.	1.4	0
326	Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood, 2004, 103, 3979-3981.	1.4	219
327	Three-Module Signaling Endo-Domain Artifical T-Cell Receptor Which Transmits CD28, OX40 and CD3-Î¶ Signals Enhances IL-2 Release and Proliferative Response in Transduced Primary T-Cells.. Blood, 2004, 104, 1747-1747.	1.4	2
328	Evaluation of Aprepitant for Treatment of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting in Patients Undergoing Autologous Stem Cell Transplantation.. Blood, 2004, 104, 5041-5041.	1.4	2
329	LMP2-Cytotoxic T Lymphocyte Therapy for Relapsed EBV Positive Lymphoma.. Blood, 2004, 104, 3276-3276.	1.4	2
330	Rasburicase Improves Renal Function and Uric Acid Nephropathy in Patients Developing Acute Renal Failure after Conditioning for Hematopoetic Stem Cell Transplant (HSCT).. Blood, 2004, 104, 1142-1142.	1.4	0
331	Flanking-Sequence Exponential Anchored (FLEA) PCR - a Sensitive and Highly Specific Method for Detecting Retroviral Integrant-Host-Junction Sequences.. Blood, 2004, 104, 2112-2112.	1.4	1
332	Multiple Integration Events into Several Putative Oncogenes Was Required To Cause Leukemogenesis in Two Primate Recipients of RCR Contaminated Stem-Cells.. Blood, 2004, 104, 2102-2102.	1.4	3
333	Retrovirus-Transduced T Cell Blasts Have Not Only Antigen-Presenting Capabilities but Also Suppressor Regulatory T Cell-Inducing Capability.. Blood, 2004, 104, 3855-3855.	1.4	0
334	High Incidence but Low Morbitiy of Early Cytomegalovirus (CMV) Infections Following Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation with Alemtuzumab and Ganciclovir Prophylaxis.. Blood, 2004, 104, 5098-5098.	1.4	0
335	Inducible Caspase 9 as a Safety Switch in Genetically Modified Cytotoxic T Cells.. Blood, 2004, 104, 1743-1743.	1.4	0
336	Complementâ€Fixing CD45 Monoclonal Antibodies to Facilitate Stem Cell Transplantation in Mouse and Man. Annals of the New York Academy of Sciences, 2003, 996, 80-88.	3.8	19
337	Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. Cancer Treatment Reviews, 2003, 29, 3-10.	7.7	28
338	Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biology of Blood and Marrow Transplantation, 2003, 9, 273-281.	2.0	24
339	Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood, 2003, 101, 1905-1912.	1.4	182
340	Adoptive T-Cell Therapy for EBV-Associated Post-Transplant Lymphoproliferative Disease. Acta Haematologica, 2003, 110, 139-148.	1.4	43
341	Adoptive T-Cell Therapy for Epstein-Barr Virus-Positive Hodgkinâ€™s Disease. Acta Haematologica, 2003, 110, 149-153.	1.4	9
342	Immunotherapy for Epsteinâ€Barr Virusâ€Associated Cancers in Children. Oncologist, 2003, 8, 83-98.	3.7	57

#	Article	IF	Citations
343	Immunotherapy of Hematologic Malignancy. Hematology American Society of Hematology Education Program, 2003, 2003, 331-349.	2.5	67
344	Large-Scale Expansion of Dendritic Cell-Primed Polyclonal Human Cytotoxic T-Lymphocyte Lines Using Lymphoblastoid Cell Lines for Adoptive Immunotherapy. Journal of Immunotherapy, 2003, 26, 241-256.	2.4	59
345	Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood, 2003, 102, 2292-2299.	1.4	139
346	Generation of EBV-Specific CD4+ Cytotoxic T Cells from Virus Naive Individuals. Journal of Immunology, 2002, 168, 909-918.	0.8	101
347	Intravenous Cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient. Transplantation, 2002, 74, 1050-1052.	1.0	68
348	Adapting a transforming growth factor Î²â€“related tumor protection strategy to enhance antitumor immunity. Blood, 2002, 99, 3179-3187.	1.4	310
349	Autologous Epstein-Barr virus (EBV)â€“specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood, 2002, 100, 4059-4066.	1.4	141
350	Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2002, 8, 1-8.	2.0	44
351	Immunotherapy to reconstitute immunity to DNA viruses. Seminars in Hematology, 2002, 39, 41-47.	3.4	17
352	Immunotherapy for Post-Transplant Lymphoproliferative Disease. British Journal of Haematology, 2002, 118, 728-740.	2.5	55
353	Genetically engineered T-cells for adoptive immunotherapy. Current Opinion in Molecular Therapeutics, 2002, 4, 467-75.	2.8	2
354	Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Research, 2002, 62, 7195-9.	0.9	46
355	Gene therapy for paediatric leukaemia. Expert Opinion on Biological Therapy, 2001, 1, 663-674.	3.1	5
356	An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood, 2001, 97, 835-843.	1.4	249
357	Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: A potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. International Journal of Cancer, 2001, 93, 706-713.	5.1	80
358	Gene-Marking studies of hematopoietic cells. International Journal of Hematology, 2001, 73, 14-22.	1.6	11
359	GENERATION OF AUTOLOGOUS EPSTEIN-BARR VIRUS???SPECIFIC CYTOTOXIC T CELLS FOR ADOPTIVE IMMUNOTHERAPY IN SOLID ORGAN TRANSPLANT RECIPIENTS1. Transplantation, 2001, 72, 1078-1086.	1.0	81
360	Immunotherapy for malignancies and viral infections. Current Opinion in Organ Transplantation, 2000, 5, 197-202.	1.6	2

#	Article	IF	Citations
361	Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease. Journal of Clinical Immunology, 2000, 20, 1-9.	3.8	16
362	The Use of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus Induced Lymphoma in Transplant Recipients. Leukemia and Lymphoma, 2000, 39, 455-464.	1.3	23
363	HAEMOPOIETIC STEM CELL TRANSPLANTATION FROM UNRELATED DONORS.. British Journal of Haematology, 1999, 105, 2-6.	2.5	10
364	Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. , 1999, 14, 154-156.		29
365	Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Current Opinion in Oncology, 1999, 11, 96.	2.4	40
366	Upper airway obstruction and pulmonary abnormalities due to lymphoproliferative disease following bone marrow transplantation in children. Pediatric Radiology, 1998, 28, 492-496.	2.0	4
367	Increased Transduction Efficiency of Primary Hematopoietic Cells by Physical Colocalization of Retrovirus and Target Cells. Stem Cells and Development, 1998, 7, 217-224.	1.0	10
368	Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T-Lymphocytes to Patients with Relapsed EBV-Positive Hodgkin Disease. Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas. Human Gene Therapy, 1998, 9, 1237-1250.	2.7	24
369	Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virusâ€“Induced Lymphoma in Allogeneic Transplant Recipients. Blood, 1998, 92, 1549-1555.	1.4	269
370	A Yeast Artificial Chromosome (YAC) Contig Encompassing the Critical Region of the X-Linked Lymphoproliferative Disease (XLP) Locus. Genomics, 1997, 39, 55-65.	2.9	23
371	Outcomes of transplantation with matched-sibling and unrelateddonor bone marrow in children with leukaemia. Lancet, The, 1997, 350, 767-771.	13.7	167
372	Adoptive cellular immunotherapy for EBV lymphoproliferative diseases. Immunological Reviews, 1997, 157, 217-222.	6.0	199
373	Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity. Trends in Molecular Medicine, 1997, 3, 24-30.	2.6	27
374	Longâ€“term restoration of immunity against Epsteinâ€“Barr virus infection by adoptive transfer of geneâ€“modified virusâ€“specific T lymphocytes. Nature Medicine, 1996, 2, 551-555.	30.7	820
375	Measuring geneâ€“transfer efficiency. Nature Medicine, 1996, 2, 1280-1281.	30.7	14
376	Use of Double Marking with Retroviral Vectors to Determine Rate of Reconstitution of Untreated and Cytokine Expanded CD34+Selected Marrow Cells in Patients Undergoing Autologous Bone Marrow Transplantation. St. Jude Children's Research Hospital, Memphis, Tennessee. Human Gene Therapy, 1996, 7, 655-667.	2.7	10
377	Adoptive Immunotherapy for Epstein-Barr Virus-Related Lymphoma. Leukemia and Lymphoma, 1996, 23, 213-220.	1.3	24
378	Gene transfer for the therapy of hematologic malignancy. Current Opinion in Hematology, 1995, 2, 417-422.	2.5	3

#	Article	IF	Citations
379	Production of Genetically Modified Epstein-Barr Virus-Specific Cytotoxic T Cells for Adoptive Transfer to Patients at High Risk of EBV-Associated Lymphoproliferative Disease. Stem Cells and Development, 1995, 4, 73-79.	1.0	115
380	T cell receptor repertoire of CD4 + and CD8 + T cell subsets in the allogeneic bone marrow transplant recipient. Cancer Immunology, Immunotherapy, 1995, 41, 104-110.	4.2	4
381	Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T Lymphocytes to Recipients of Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Grafts. St. Jude Children's Research Hospital, Memphis, Tennesse. Human Gene Therapy, 1994, 5, 381-397.	2.7	85
382	7 Cytokine gene transfer in the therapy of malignancy. Best Practice and Research: Clinical Haematology, 1994, 7, 135-151.	1.1	2
383	Assessment of the Efficacy of Purging by Using Gene Marked Autologous Marrow Transplantation for Children with AML in First Complete Remission. St. Jude Children's Research Hospital, Memphis, Tennessee. Human Gene Therapy, 1994, 5, 481-499.	2.7	30
384	Use of Marker Genes to Investigate the Mechanism of Relapse and the Effect of Bone Marrow Purging in Autologous Transplantation for Stage D Neuroblastoma. St. Jude Children's Research Hospital. Human Gene Therapy, 1993, 4, 809-820.	2.7	11
385	Graft-versus-host reactions and bone-marrow transplantation. Current Opinion in Immunology, 1991, 3, 752-757.	5.5	20
386	Graft versus leukaemia effects after marrow transplantation in man. Best Practice and Research: Clinical Haematology, 1991, 4, 727-749.	1.1	9
387	Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. British Journal of Haematology, 1991, 77, 237-244.	2.5	38
388	Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. British Journal of Haematology, 1990, 75, 499-505.	2.5	30
389	Delayed Induction of Proto-Oncogene Expression in B-CLL Cells by Tumor Necrosis Factor. Leukemia and Lymphoma, 1990, 3, 37-43.	1.3	5
390	Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM-CSF. British Journal of Haematology, 1989, 73, 468-474.	2.5	10
391	Spontaneous and interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy. British Journal of Haematology, 1989, 72, 122-126.	2.5	22
392	ALLOGENEIC RED BLOOD CELLS FAIL TO INDUCE HAEMAGGLUTINATING ANTIBODIES OR CELLULAR ALLOIMMUNITY IN RATS AND ARE IMMUNOSUPPRESSIVE. Transplantation, 1979, 28, 144-148.	1.0	11
393	A method for preparing leucocyte depleted erythrocytes from rat blood. Journal of Immunological Methods, 1978, 22, 389-391.	1.4	3
394	Adoptive Immunotherapy. , 0, , 920-935.		0